成人无码高潮av在线观看_欧洲极品少妇_夂久亚州精华国产精华华液_在线观看亚洲AV每日更新无码_亚洲国产精品无码久久一线_亚洲精品区午夜亚洲精品区

泰邦生物集團(tuán) China Biologic Products 中國生物制品  
China Biologic Products, Inc. (NASDAQ: CBPO) 是國家承認(rèn)的最大的非國有血漿生物醫(yī)藥制品公司，通過我們旗下的山東泰邦生物制品有限公司、貴陽大林生物科技公司，以及我們投資于西安回天血液制品的產(chǎn)品，我們已經(jīng)成為了血漿生物醫(yī)藥制品行業(yè)的綜合供應(yīng)商，我們有能力跨越，以從血漿存儲(chǔ)，到研究發(fā)展，到產(chǎn)品制造和全面商業(yè)化。我們的主要產(chǎn)品，人類血蛋白和免疫球蛋白，最常被用于治療威脅生命的各種情況，如低白蛋白，血友病及其他血液病。我們目前有20個(gè)銷售血漿產(chǎn)品和新產(chǎn)品的生產(chǎn)線，以推動(dòng)大中國市場(chǎng)未來的血液產(chǎn)品市場(chǎng)的發(fā)展。為了配合我們的有機(jī)增長(zhǎng)，我們繼續(xù)尋求戰(zhàn)略收購機(jī)會(huì)，擴(kuò)大我們?cè)谥袊貐^(qū)的血漿儲(chǔ)備能力，并加強(qiáng)我們的研發(fā)和技術(shù)上的能力。

China Biologic Products Inc。泰邦生物是一家在納斯達(dá)克交易所上市的公司，股票代碼CBPO，公司總部設(shè)于中國北京市。泰邦生物是最大的的非國有制的血漿生物醫(yī)藥制品公司，旗下?lián)碛凶庸旧綎|泰邦生物制品有限公司，貴陽大林生物科技公司，以及西安回天血液制品公司的股份，我們已經(jīng)成為了在血漿收集、開發(fā)和生產(chǎn)新的血液藥物、并將其終端產(chǎn)品商品化的綜合供應(yīng)商。我們的產(chǎn)品主要針對(duì)緊急醫(yī)療情況，以及預(yù)防和治療威脅生命的疾病。我們的產(chǎn)品在的終端用戶是醫(yī)院和其他衛(wèi)生保健機(jī)構(gòu)。

China Biologic Products, Inc. (Nasdaq: CBPO), is one of the China’s largest non-state-owned fully integrated plasma-based biopharmaceutical companies. Our products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases that include rabies, tetanus, and hepatitis B.

Our core capabilities include plasma collection, research and development, production, and commercialization of biopharmaceutical products.

Currently we produce more than 20 plasma-based products and have a pipeline of new and developing products to drive our future in China’s growing plasma market. To complement our organic growth, we consider acquisitions to expand our plasma collection capabilities in China. We are constantly at work to enhance our R&D and technological capabilities to create new products and to improve our existing products and processes.

We sell directly to hospitals and other healthcare facilities in China and are reducing the use of independent distributors.

Our headquarters is in the city of Beijing. We manufacture in our indirect majority-owned subsidiaries, Shandong Taibang Biological Products and Guiyang Dalin Biologic Technologies, and have an equity investment in Xi’an Huitian Blood Products.